Medicare AdvantagePrior AuthMedium impact
Alternate nilotinib products (Danziten, nilotinib tartrate-Cipla) (Revised)
Humana·Oncology, Hematology·Medicare Advantage
We identified it
Jul 14, 2026
Summary
This is a revised Prior Authorization policy for alternate nilotinib products (Danziten and nilotinib tartrate-Cipla) for Medicare Advantage members. The policy establishes requirements for prior authorization when prescribing these alternative nilotinib formulations. Billing teams must implement prior auth procedures for these specific drug products to avoid claim denials.
Action Required
Immediately: Billing and clinical teams must implement prior authorization procedures for Danziten and nilotinib tartrate-Cipla (Cipla) nilotinib products for all Medicare Advantage members. Update pharmacy billing system and EMR to flag these specific drug products for mandatory prior auth submission before dispensing. Coordinate with pharmacy and prescribing providers to ensure prior auth requests are submitted with appropriate medical necessity documentation. Contact Humana Medicare Advantage plans for specific prior auth submission procedures using the policy reference URL (https://dctm.humana.com/Mentor/Web/v.aspx?objectID=090009298a57b94b). Failure to obtain prior authorization will result in claim denials for these alternate nilotinib formulations.